Halozyme stockholders elect three Class I directors and approve 2023 auditor at annual meeting

HALOZYME THERAPEUTICS, INC.

All three Class I director nominees elected: Connaughton, Miyashita, Posard, with majority votes.
Advisory vote on executive compensation approved with 107.6M for vs 4.7M against (95.8% support).
Stockholders chose annual frequency for future advisory votes on executive compensation (110.4M for one year).
Ratification of Ernst & Young as auditor for FY2023 approved with 123.3M votes for (98.8% of votes cast).
Turnout: 124.5M shares represented out of 135.4M outstanding (92% attendance).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers at the 2023-05-05 meeting.

Proposal: say on pay frequency
Outcome: passed
Meeting: 2023-05-05

Exact text from the filing

Proposal 3 : The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers was as follows: One Year Two Years Three Years Abstain 110,411,006 145,264 1,760,124 83,512

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

HALOZYME THERAPEUTICS, INC. shareholders approved A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-05 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-05

Exact text from the filing

Proposal 4 : The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: Votes For Votes Against Abstain Broker Non-Votes 123,271,829 1,153,279 103,055 — The foregoing proposal was approved.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the compensation of the Company's named executive officers at the 2023-05-05 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-05

Exact text from the filing

Proposal 2 : The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 107,628,112 4,657,698 114,096 12,128,257 The foregoing proposal was approved.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

HALOZYME THERAPEUTICS, INC. shareholders approved Election of three Class I directors to hold office for a three-year term expiring at the 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2023-05-05 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-05

Exact text from the filing

On May 5, 2023, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders.

View on SEC.gov

560 shareholder votes filed in the last 30 days. Browse all shareholder votes →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.